Company Updates covers news from Brilliant Blue Biosciences. Research & Industry News highlights relevant developments published by external sources, summarised and attributed to them.
The BaseMap ABE launch offers genome-wide measurements in relevant cells to support off-target characterisation during therapeutic development. The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance.
Their planned workflow combines capillary isoelectric focusing fractionation and mass photometry to examine bispecific antibodies and biosimilars. The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The company launched to develop protein amplification technology intended for highly sensitive diagnostic testing. The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The acquisition brings InDevR's multiplexing capabilities into SSI Diagnostica's diagnostics and vaccine-development portfolio. The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Cellares will support automated manufacturing and release assays for gene-edited haematopoietic stem-cell therapies under development at Stanford Medicine. The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The Houston facility expands Avance Biosciences' capacity for functional and potency testing during therapy development. The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The collaborators plan to extend Cell Q, an automated platform for in-process and release testing at commercial manufacturing scale. The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.
Prefer to talk it through? Book a 30-minute discovery call
